The Saudi Arabian sovereign wealth fund, PIF, has launched a commercial-scale contract development and manufacturing organization called Lifera to boost the local biopharmaceutical industry
Lifera will focus on manufacturing life-saving and essential pharmaceutical products, including insulins, vaccines, plasma therapeutics, monoclonal antibodies, cell and gene therapies, and innovative small molecules.
The goal is to create partnerships with leading local and international companies and attract targeted investments to boost local capacity and drive the development of domestic manufacturing in this sector.
Lifera aims to drive formulation development, medicine development, manufacturing, and testing services for sterile pharmaceutical products.
PIF has also invested in the National Unified Procurement Co. to enable the supply chain of medicines.
Lifera aims to drive formulation development, medicine development, manufacturing, and testing services for sterile pharmaceutical products.
PIF has also invested in the National Unified Procurement Co. to enable the supply chain of medicines.
